YYYong-Feng Yang

Yong-Feng Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yong-Feng Yang has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mechanistic insights and therapeutic potential of hispidulin in hepatocellular carcinoma: a bioinformatics and experimental study

    by Xulei Zhang, Yuan Yang, Zhiyuan Xu, Miaoyang Chen, Anyin Yang, Yongfeng Yang

    Background: As a natural compound present in a variety of plants, hispidulin has an inhibitory effect on tumors. Methods: In this study, we combined network pharmacology, bioinformatics methods and experimental verification to explore the potential targets of hispidulin in inhibiting hepatocellular carcinoma. Results: The network pharmacology analysis showed that the pharmacokinetic properties of hispidulin conformed to the Lipinski's five rules, and it had no hepatotoxicity, carcinogenicity, cytotoxicity, immunotoxicity, mutagenicity, and had the potential to be developed as a drug. The results of network pharmacology and bioinformatics analysis showed that hispidulin may interfere with the occurrence and progression of hepatocellular carcinoma by affecting CDK1, SRC, CCNB1, AURKB and PI3K-AKT signaling pathways. In vitro, hispidulin can inhibit the growth of hepatocellular carcinoma, induce apoptosis and inhibit migration of hepatocellular carcinoma cells. Down-regulate the expression of CDK1, CCNB1, SRC, AURKB protein and weaken the PI3K-AKT pathway signal. It has no obvious toxicity to normal liver cells. Conclusions: Hispidin can inhibit the occurrence and progression of hepatocellular carcinoma through multiple targets, showing good anti-tumor efficacy in vitro, and has the potential to develop new therapeutic drugs for hepatocellular carcinoma.

  • Baicalein Induces Hepatic Stellate Cell Senescence and Attenuates Liver Fibrosis via CEBPZ/p53/HK2-Mediated Glycolysis Inhibition

    by Shuling Chen, Ruiqi Li, Caiyun Zhang, Jun Guo, Anyin Yang, Dawei Yang, Tianhao Mao, Hongli Liu, Hao Ren, Zihao Liang, et al.


  • Open Access

    Complement C3 predicting acute-on-chronic liver failure in cirrhotic patients with bacterial infection within 90 days: a cohort study

    by Shuling Chen, Ruiqi Li, Hongli Liu, Xiaoning Feng, Hui Zhou, Wenquan Zeng, Hao Ren, Qingfang Xiong, Caiyun Zhang, Xixuan Wang, et al.

    Objective: Cirrhotic patients with bacterial infections (BI) face high risks of acute-on-chronic liver failure (ACLF) and mortality. This study assessed the diagnostic value of serum complement component 3 (C3) for predicting 90-day ACLF and mortality in this population. Methods: We prospectively analyzed clinical data from 105 cirrhotic patients with BI (mean age 57.2 ± 11.6 years; 57 male) admitted to the Second Hospital of Nanjing between September 2023 and March 2024. Primary outcomes were ACLF development and mortality within 90 days. Results: Thirty-one patients (29.5%) developed ACLF within 90 days. Lower C3 levels independently predicted both ACLF [hazard ratio (HR): 0.14, 95% confidence interval (CI): 0.02–0.93; P = 0.04) and mortality (HR: 0.10, 95% CI: 0.00–0.89; P = 0.01). Time-dependent receiver operating characteristic analysis showed C3 predicted ACLF with AUROCs of 0.76 (30 day), 0.73 (60 day), and 0.72 (90 day). For mortality, areas under the time-dependent receiver operating characteristic curves (AUROCs) were 0.76 (30 day), 0.69 (60 day), and 0.68 (90 day). A cutoff of 0.66 g/L was established using etiology-adjusted restricted cubic spline. C3 correction improved the predictive AUROCs of Child–Turcotte–Pugh, Model of End-Stage Liver Disease, and the Chronic Liver Failure Consortium Acute Decompensation scores for mortality (all P > 0.05). Random forest regression identified C3 among the top 10 risk factors for ACLF development. Conclusion: Serum C3 demonstrates significant prognostic value as a predictor for 90-day ACLF and mortality in cirrhotic patients with bacterial infections, offering potential clinical utility in risk stratification.

  • Open Access

    Author correction to “Up-regulation of glyclipid transfer protein by bicyclol causes spontaneous restriction of hepatitis C virus replication” [Acta Pharm Sin B 9 (2019) 769–781]

    by Menghao Huang, Hu Li, Rong Xue, Jianrui Li, Lihua Wang, Junjun Cheng, Zhouyi Wu, Wenjing Li, Jinhua Chen, Xiaoqin Lv, et al.

  • [Granulomatous disease with liver injury as the main manifestation].

    by H L Liu, Q F Xiong, Y F Yang

    Hepatic granuloma is a kind of disease caused by both infection or non-infection etiologies, and it is found in approximately 2% to 15% of liver biopsies. Some of which could be identified by the pathological morphology. This article reviews the common etiology, pathological manifestations, diagnosis, and differential diagnosis of hepatic granuloma, which is hopeful to improve clinicians' and pathologists' awareness.

  • [A case report of secondary hemochromatosis caused by a mutation in the ETV6 gene].

    by X L Zhang, Y H Weng, Y F Yang

    血色病常分为原发性及继发性,临床以继发性血色病较为常见,且临床症状多不典型,易引起误诊误治。现介绍1例以肝功能异常及3系减少就诊的继发性血色病患者,全外显子检测提示ETV6基因变异,以期启示临床,找准病因,及时干预,改善患者预后。

  • Open Access

    Study on the mechanism of action of Scutellaria barbata on hepatocellular carcinoma based on network pharmacology and bioinformatics

    by An-Yin Yang, Hong-Li Liu, Yong-Feng Yang

    Background: Hepatocellular carcinoma is one of the most common cancers with the characteristics of invasion and high mortality. Current forms of prevention remain severe. Scutellaria barbata is widely used in traditional Chinese medicine treatment of various tumors. This study explored the mechanism of Scutellaria barbata in the treatment of hepatocellular carcinoma by network pharmacology and bioinformatics.Methods: The active ingredients of Scutellaria barbata and potential targets for the treatment of hepatocellular carcinoma were collected by network pharmacology. The protein interaction network was constructed to screen the core targets, and the association between the core targets and diseases was further verified by bioinformatics methods. Finally, the active ingredients corresponding to the targets closely related to the disease were screened for AMDE characteristics analysis. Molecular docking of drug-like ingredients with corresponding targets was performed. We used CCK-8 kit to determine the effect of active ingredients on cell proliferation.Results: 29 candidate active ingredients and 461 related targets of Scutellaria barbata were screened. A total of 8238 potential therapeutic targets for hepatocellular carcinoma were indentified. Finally, 373 potential targets for the treatment of HCC were obtained. The active ingredients: wogonin, Rhamnazin, eriodictyol, quercetin, baicalein, and luteolin, etc. The core targets were CDK1, CDK4, SRC, and E2F1. A total of 3056 GO enrichment entries were obtained, and 180 enrichment results were obtained by KEGG pathway analysis. Genes were mainly enriched in PI3K-Akt signaling pathway, IL-17 signaling pathway, TNF signaling pathway, apoptosis pathway, and hepatocellular carcinoma pathway. Molecular docking results showed that the screened compounds had strong binding ability with the corresponding target proteins. CCK8 assays showed that Rhamnazin and Luteolin suppressed the proliferation of HCC cells significantly compared with controls.Conclusion: This study revealed that the mechanism of Scutellaria barbata in the treatment of hepatocellular carcinoma may be that the active ingredients inhibit the expression of core genes and block the PI3K-AKT signaling pathway to inhibit the proliferation, and migration and induce apoptosis of cancer cells.


  • Open Access

    Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis

    by Hong-Li Liu, An-Yin Yang, Qing-Fang Xiong, Yan-Dan Zhong, Du-Xian Liu, Ping Huang, Xiao-Ning Feng, Yu Zhang, Yong-Feng Yang

    Background: Aberrant cytokeratin 7 expression by hepatocytes (CK7+Hs) is the hallmark characteristic of cholestasis diseases, especially in ductopenia diseases such as primary biliary cholangitis (PBC). This study attempted to evaluate the differences and relationships between the clinical and histological features of aberrant cytokeratin 7 (CK7) expression by hepatocytes in PBC patients.Methods: The clinicopathological data of patients diagnosed with PBC at the Second Hospital of Nanjing between January 2016 and September 2018 were analysed with SPSS 20.0.Results: Eighty-nine PBC patients who underwent liver biopsy were enrolled in this study, and 15, 29 and 45 patients had aberrant CK7 expression by hepatocytes (CK7+Hs (2 +), CK7+Hs (1 +), and CK7−Hs, respectively). There were significant differences in TB, DB, ALP, TA, IgM, interface activity, and ductopenia grade between patients with CK7−Hs and CK7+Hs (2 +) (P < 0.05). The ductopenia grade was also significantly different between patients with CK7+Hs (2 +) and CK7+Hs (1 +) according to sex (P < 0.05). Upon merging the data of CK7+Hs (2 +) and CK7+Hs (1 +) into CK7+Hs, we found significant differences in AMA, AMA-M2, anti-gp210, TB, DB, ALP, TA, IgM, fibrosis, and ductopenia grade between CK7+Hs and CK7−Hs (P < 0.05). The odds ratios (ORs) (and 95% confidence intervals (CIs)) of CK7+Hs according to anti-gp210, ductopenia grade, and interface activity were 6.413 (95% CI 1.363–30.162), 4.145 (95% CI 1.898–9.052) and 3.247 (95% CI 1.556–6.775), respectively (P < 0.05). Spearman's rank correlation according to interface activity and ductopenia grade in patients with CK7+Hs (2 + , 1 + , 0) wasr = 0.359 (P = 0.001) andr = 0.396 (P < 0.001), respectively.Conclusion: CK7+Hs serves as a cholestasis index of PBC and are associated with the ductopenia grade and interface activity. Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis.


  • Open Access

    Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

    by Ying Qu, Yan-Yan Song, Cheng-Wei Chen, Qing-Chun Fu, Jun-Ping Shi, Yun Xu, Qing Xie, Yong-Feng Yang, Yong-Jian Zhou, Liang-Ping Li, et al.

    INTRODUCTION: To evaluate the diagnostic performance of ultrasound attenuation parameter (UAP) and liver stiffness measurement (LSM) by FibroTouch for diagnosis of hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). METHODS: We recruited 237 patients undergoing FibroTouch and liver biopsy within 2 weeks. The pathological findings of liver biopsy were scored by Nonalcoholic Steatohepatitis Clinical Research Network, and the diagnostic accuracy of UAP for steatosis and LSM for fibrosis was evaluated by area under the receiver operating characteristic curve (AUROC). The impacts of histological parameters on UAP and LSM were analyzed, and diagnostic performance of FibroTouch UAP and LSM was compared with other noninvasive biomarkers. RESULTS: The success rate of FibroTouch examination was 96.51%. The AUROC of UAP for diagnosis of steatosis ≥S1, ≥S2, and S3 was 0.88, 0.93, and 0.88, and the cutoff values were 244, 269, and 296 dB/m, respectively. The AUROC of LSM for the diagnosis of fibrosis stages ≥F2, ≥F3, and F4 was 0.71, 0.71, and 0.77, and the cutoff values were 9.4, 9.4, and 11 kPa, respectively. Multiple regression analysis showed that LSM was positively correlated with degree of fibrosis and NAFLD activity score. UAP was positively correlated with liver steatosis. The diagnostic performance of UAP for steatosis was significantly superior to that of the hepatic steatosis index. DISCUSSION: FibroTouch has a low failure rate with moderate to high diagnostic performance for discriminating the steatosis degree and fibrosis stage and is suitable for clinical evaluation and monitoring of patients with NAFLD.


  • [Progress in the diagnosis and treatment of idiopathic non-cirrhotic portal hypertension].

    by Y Zhang, Y F Yang

    Idiopathic non-cirrhotic portal hypertension is a rare group of clinical syndromes characterized by clinical manifestations of portal hypertension in the absence of histological manifestations of liver cirrhosis, and with the exclusion of known intrahepatic and extrahepatic causes of portal hypertension. Importantly, its etiology and pathogenesis are unclear, but it has been determined to be related to the development of intrahepatic vascular disease. It is currently believed that possible pathogenic mechanisms include immune disorders, chronic infections, drug-related poisoning or injury, microthrombosis, genetic abnormalities, etc. The most common clinical manifestations are esophagogastric varices and splenomegaly. Ascites and hepatic encephalopathy are the least common. Laboratory test demonstrates anemia, leukopenia, and thrombocytopenia due to hypersplenism, and normal or mild liver function abnormality. In addition, in the preclinical stage, despite the presence of abnormal portal vein during liver biopsy, no signs of portal hypertension can be detected in some patients. Therefore, the diagnosis is based on the diagnosis of exclusion and mandatory liver biopsy. The overall prognosis of idiopathic non-cirrhotic portal hypertension is better than that of patients with liver cirrhosis, but symptomatic treatment (controlling gastroesophageal varices bleeding and preventing thrombosis) is still the main treatment.